{
    "clinical_study": {
        "@rank": "127779", 
        "arm_group": {
            "arm_group_label": "Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo copper Cu 64-DOTA-trastuzumab PET scan."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies copper Cu 64 tetraazacyclododecane-tetraacetic acid\n      (DOTA)-trastuzumab positron emission tomography (PET) in studying patients with gastric\n      cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET, may help doctors\n      plan the best treatment."
        }, 
        "brief_title": "Labeled PET in Studying Patients With Gastric Cancer", 
        "condition": [
            "Adenocarcinoma of the Gastroesophageal Junction", 
            "Diffuse Adenocarcinoma of the Stomach", 
            "Intestinal Adenocarcinoma of the Stomach", 
            "Mixed Adenocarcinoma of the Stomach", 
            "Recurrent Gastric Cancer", 
            "Stage IA Gastric Cancer", 
            "Stage IB Gastric Cancer", 
            "Stage IIA Gastric Cancer", 
            "Stage IIB Gastric Cancer", 
            "Stage IIIA Gastric Cancer", 
            "Stage IIIB Gastric Cancer", 
            "Stage IIIC Gastric Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To compare tumor uptake of 64Cu-DOTA-trastuzumab (copper Cu 64-DOTA-trastuzumab) in\n      gastric cancer patients with pathologic evaluation of tumor human epidermal growth factor\n      receptor 2 (HER2)/neu expression.\n\n      II. To compare copper Cu 64-DOTA-trastuzumab-PET scan with standard radiographic imaging for\n      staging patients with gastric cancer.\n\n      OUTLINE:\n\n      Patients undergo copper Cu 64-DOTA-trastuzumab PET scan."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have a histologic diagnosis of gastric or gastroesophageal junction\n             adenocarcinoma; (the first 2 patients must be HER2 3+ by immunohistochemistry [IHC]\n             or fluorescence in situ hybridization [FISH] positive)\n\n          -  Patient must be a candidate for surgical resection as determined by surgical oncology\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\n          -  Women of childbearing potential must have a negative serum pregnancy test within 14\n             days of copper Cu 64-DOTA administration and must have agreed to use an effective\n             contraceptive method; women of child-bearing potential and men must agree to use\n             adequate contraception (hormonal or barrier method of birth control or abstinence)\n             prior to study entry and for four months following duration of study participation;\n             should a woman become pregnant or suspect that she is pregnant while participating on\n             the trial, she should inform her treating physician immediately\n\n          -  Computed tomography (CT)/magnetic resonance imaging (MRI) scan must be obtained\n             within 3 weeks prior to study entry\n\n          -  Absolute neutrophil count >= 1,500/mcl\n\n          -  Platelet count >= 100,000/mcl\n\n          -  Creatinine =< 1.3 mg/dL or a measured creatinine clearance >= 60 cc/min\n\n          -  Bilirubin =< 1.5 mg/dL\n\n          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) no greater than 1.5\n             times the upper limit of normal\n\n          -  Patients currently being treated for severe infections or who are recovering from\n             major surgery or other intercurrent illnesses are ineligible until recovery is deemed\n             complete by the investigator\n\n          -  Patients must have normal cardiac ejection fraction\n\n          -  All subjects must have the ability to understand and the willingness to sign a\n             written informed consent\n\n          -  For patients that have received prior therapy: all toxicities should recover to grade\n             0 or 1 prior to day 1\n\n        Exclusion Criteria:\n\n          -  Patients with any grade electrolyte abnormalities that are unable to be corrected by\n             day 1\n\n          -  Impaired cardiac function including any one of the following: complete left bundle\n             branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome,\n             presence of ventricular tachyarrhythmias, clinically significant resting bradycardia\n             (< 50 beats per minute), QT interval corrected for Fridericia's formula (QTcF) > 450\n             msec on screening electrocardiogram (ECG), or right bundle branch block + left\n             anterior hemiblock (bifascicular block)\n\n          -  Presence of atrial fibrillation\n\n          -  Previous history of angina pectoris or acute myocardial infarction (MI) within 6\n             months\n\n          -  Congestive heart failure (New York Heart Association functional classification\n             III-IV)\n\n          -  Uncontrolled hypertension (mmHg > 160 systolic or > 90 diastolic)\n\n          -  Brain or leptomeningeal metastases\n\n          -  Patients with an active, bleeding diathesis or requiring therapeutic anticoagulation\n\n          -  Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C;\n             baseline testing for HIV and hepatitis C is not required\n\n          -  Patients should not have any uncontrolled illness including ongoing or active\n             infection\n\n          -  Patients may not be receiving any other investigational agents, or concurrent\n             biological, chemotherapy, or radiation therapy\n\n          -  Subjects, who in the opinion of the investigator, may not be able to comply with the\n             safety monitoring requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939275", 
            "org_study_id": "13229", 
            "secondary_id": [
                "NCI-2013-01721", 
                "13229"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)", 
                "description": "Undergo Copper Cu 64-DOTA-trastuzumab PET scan", 
                "intervention_name": "copper Cu 64-DOTA-trastuzumab", 
                "intervention_type": "Radiation", 
                "other_name": "64Cu-DOTA-trastuzumab"
            }, 
            {
                "arm_group_label": "Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)", 
                "description": "Undergo Copper Cu 64-DOTA-trastuzumab PET scan", 
                "intervention_name": "positron emission tomography", 
                "intervention_type": "Device", 
                "other_name": [
                    "FDG-PET", 
                    "PET", 
                    "PET scan", 
                    "tomography, emission computed"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Copper", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "vchung@coh.org", 
                "last_name": "Vincent Chung", 
                "phone": "626-471-9200"
            }, 
            "facility": {
                "address": {
                    "city": "Duarte", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91010"
                }, 
                "name": "City of Hope Medical Center"
            }, 
            "investigator": {
                "last_name": "Vincent Chung", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "64Cu-DOTA-trastuzumab Positron Emission Tomography in Patients With Gastric Cancer", 
        "overall_official": {
            "affiliation": "City of Hope Medical Center", 
            "last_name": "Vincent Chung", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Parameterized in terms of single-voxel maximum values peak standardized uptake value (SUVmax) and whole-tumor volumes of interest (SUVwhtum). Ratios of tumor to non-tumor activity concentration will be calculated. Receiver-operator curve (ROC) analysis will be performed to estimate optimal cutoff values of SUVmax, SUVwhtum, tumor:background, and tumor:organ ratios for classifying tumors as  \"HER2 positive\" or \"HER2 negative\".", 
                "measure": "Tumor uptake of copper Cu 64-DOTA trastuzumab", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Estimated with a 95% confidence interval (CI) half-width of 21%.", 
                "measure": "Percent of patients whose tumors image with Cu-PET", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Estimated with a 95% CI half-width of 21%.", 
                "measure": "Percent of samples where the surgeon was confident they could identify areas on the tumor that corresponded to high or low areas of Cu-PET uptake", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Positive and negative areas of the tumor will be sent to pathology for confirmation. This will be exploratory.", 
                "measure": "Pathologic confirmation of Cu-PET SUV variation over the tumor", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Correlative of Cu-PET SUV (measured as peak SUV) and pathology will be explored. As correlation requires a continuous measure from pathology, and some pathology will use FISH and/or IHC, this will be exploratory. Comparing Cu-PET in positive cases versus negative by pathology will depend on the percent of patients deemed positive.", 
                "measure": "Pathologic confirmation of Cu-PET SUV positive or negative cases", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939275"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "City of Hope Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "City of Hope Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}